At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 91 enrolled
Drug / intervention
imatinib mesylatedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Dose Finding and Phase II Study of STI 571 in Advanced Soft Tissue Sarcoma
European Organisation for Research and Treatment of Cancer - EORTC·interventional·Posted Apr 26, 2004·Updated Sep 24, 2012
In Brief
A Phase 2 clinical trial evaluating imatinib mesylate for Endometrial Cancer and 4 related conditions. Completed, enrolled 91 participants across 16 sites in 5 countries.
Detailed Summary
RATIONALE: STI571 may interfere with the growth of cancer cells and may be an effective treatment for soft tissue sarcoma. PURPOSE: Phase I/II trial to study the effectiveness of STI571 in treating patients who have recurrent or refractory soft tissue sarcoma.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsEndometrial Cancer, Gastrointestinal Stromal Tumor, Ovarian Cancer, Sarcoma, Small Intestine Cancer
CountriesBelgium, Denmark, France, Netherlands, United Kingdom
Collaborators--
Timeline
Phase 2CompletedFinished
2000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartAug 2000
Primary CompletionApr 2001
First PostedApr 2004
TodayJul 2026
First PostedApr 26, 2004
Enrollment StartAug 1, 2000
Primary CompletionApr 1, 2001
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 22.2 years ago
Interventions
imatinib mesylatedrug